These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 28356718)

  • 1. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
    Yassin SA; Aroda VR
    Drug Des Devel Ther; 2017; 11():923-937. PubMed ID: 28356718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gliptin-gliflozin combination for treating type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2016 Aug; 12(527):1384-1388. PubMed ID: 28671793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
    Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies.
    Freeman J
    J Fam Pract; 2015 Dec; 64(12 Suppl):S59-66. PubMed ID: 26845016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical decisions. Glycemic management in a patient with type 2 diabetes.
    Hirsch IB; Molitch ME
    N Engl J Med; 2013 Oct; 369(14):1370-2. PubMed ID: 24088099
    [No Abstract]   [Full Text] [Related]  

  • 10. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1407-1417. PubMed ID: 27435042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
    McReelis KD; Lovshin JA
    Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
    [No Abstract]   [Full Text] [Related]  

  • 13. Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.
    DeFilippis EM; Givertz MM
    Curr Heart Fail Rep; 2016 Jun; 13(3):111-8. PubMed ID: 27188181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
    Avogaro A; Delgado E; Lingvay I
    Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P; White WB
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral combination therapy in primary care.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updates on cardiovascular outcome trials in diabetes.
    Schnell O; Rydén L; Standl E; Ceriello A;
    Cardiovasc Diabetol; 2017 Oct; 16(1):128. PubMed ID: 29020969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
    Choby B
    FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.